Nucleus Basalis Of Meynert Neurons In Lewy Body Disease is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
The Nucleus Basalis of Meynert (NBM) is the major cholinergic nucleus providing innervation to the entire cortical mantle. In Lewy body disease (Parkinson's disease and Dementia with Lewy Bodies), NBM degeneration is a key contributor to the characteristic cognitive decline and attentional deficits.
The NBM demonstrates:
NBM degeneration contributes to:
| Neurotransmitter | Change | Clinical Correlation |
|---|---|---|
| Acetylcholine | ↓↓ 60-80% | Cognitive impairment |
| GABA | ↓ 20-30% | Neuropsychiatric symptoms |
| Norepinephrine | ↓ 40-50% | Autonomic dysfunction |
| Serotonin | ↓ 30-40% | Depression, apathy |
| Feature | LBD | AD |
|---|---|---|
| NBM neuronal loss | 60-80% | 30-50% |
| Cortical ACh reduction | Severe | Moderate |
| Lewy bodies | Present | Absent |
| Treatment response | Cholinergics helpful | Cholinergics helpful |
The study of Nucleus Basalis Of Meynert Neurons In Lewy Body Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Whitehouse, P.J., et al. (1982). Nucleus Basalis Cholinergic Neurons in Lewy Body Disease. Science.
[2] Bohnen, N.I., et al. (2019). Cortical Cholinergic Denervation in LBD. Brain.
[3] Shimada, H., et al. (2009). NBM Imaging in Lewy Body Disease. Journal of Nuclear Medicine.
[4] Litvan, I., et al. (1998). Cholinergic Dysfunction in LBD. Neurology.
[5] Emre, M., et al. (2004). Cholinergic Therapy for LBD. Lancet Neurology.